In the KEYNOTE 224 trial, PD-L1 expression assessed by CPS score showed a correlation with the ORR benefit of pembrolizumab treatment in HCC patients (CPS≥1 32% vs CPS<1 20%); however, there was no significant correlation between TPS and therapeutic efficacy, suggesting that the combination of CPS score and TPS score may improve the predictive value of PD-L1 immunohistochemical assay (Table 2) (39). Here, CD274 is linked to hepatocellular carcinoma.